D'Alessio D A, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck J W
Department of Medicine and Physiology, University of Washington, Seattle 98195, USA.
J Clin Invest. 1996 Jan 1;97(1):133-8. doi: 10.1172/JCI118380.
Glucagon-like peptide 1 (GLP-1) is an insulinotropic hormone released after nutrient ingestion which is known to augment insulin secretion, inhibit glucagon release, and promote insulin-independent glucose disposition. To determine the overall effect of GLP-1 on glucose disposition after a meal we studied a group of healthy, conscious baboons before and after intragastric glucose administration during infusions of saline, and two treatments to eliminate the action of GLP-1: (a) exendin-[9-39] (Ex-9), a peptide receptor antagonist of GLP-1; or (b) an anti-GLP-1 mAb. Fasting concentrations of glucose were higher during infusion of Ex-9 than during saline (4.44 +/- 0.05 vs. 4.16 +/- 0.05 mM, P < 0.01), coincident with an elevation in the levels of circulating glucagon (96 +/- 10 vs. 59 +/- 3 ng/liter, P < 0.02). The postprandial glycemic excursions during administration of Ex-9 and mAb were greater than during the control studies (Ex-9 13.7 +/- 2.0 vs. saline 10.0 +/- 0.8 mM, P = 0.07; and mAb 13.6 +/- 1.2 vs. saline 10.6 +/- 0.9 mM, P = 0.044). The increments in insulin levels throughout the absorption of the glucose meal were not different for the experimental and control conditions, but the insulin response in the first 30 min after the glucose meal was diminished significantly during treatment with Ex-9 (Ex-9 761 +/- 139 vs. saline 1,089 +/- 166 pM, P = 0.044) and was delayed in three of the four animals given the neutralizing antibody (mAb 946 +/- 262 vs. saline 1,146 +/- 340 pM). Thus, elimination of the action of GLP-1 impaired the disposition of an intragastric glucose meal and this was at least partly attributable to diminished early insulin release. In addition to these postprandial effects, the concurrent elevation in fasting glucose and glucagon during GLP-1 antagonism suggests that GLP-1 may have a tonic inhibitory effect on glucagon output. These findings demonstrate the important role of GLP-1 in the assimilation of glucose absorbed from the gut.
胰高血糖素样肽1(GLP-1)是一种在摄入营养物质后释放的促胰岛素激素,已知其可增强胰岛素分泌、抑制胰高血糖素释放并促进非胰岛素依赖型葡萄糖代谢。为了确定GLP-1对餐后葡萄糖代谢的总体影响,我们研究了一组健康、清醒的狒狒,在胃内给予葡萄糖期间,分别输注生理盐水以及两种消除GLP-1作用的处理:(a)艾塞那肽-[9-39](Ex-9),一种GLP-1的肽受体拮抗剂;或(b)抗GLP-1单克隆抗体。输注Ex-9期间的空腹血糖浓度高于输注生理盐水期间(4.44±0.05 vs. 4.16±0.05 mM,P<0.01),同时循环中的胰高血糖素水平升高(96±10 vs. 59±3 ng/升,P<0.02)。给予Ex-9和单克隆抗体期间的餐后血糖波动大于对照研究期间(Ex-9 13.7±2.0 vs. 生理盐水10.0±0.8 mM,P = 0.07;单克隆抗体13.6±1.2 vs. 生理盐水10.6±0.9 mM,P = 0.044)。在葡萄糖餐吸收过程中,胰岛素水平的升高在实验条件和对照条件下并无差异,但在给予Ex-9治疗期间,葡萄糖餐后最初30分钟内的胰岛素反应显著降低(Ex-9 761±139 vs. 生理盐水1,089±166 pM,P = 0.044),并且在给予中和抗体的四只动物中有三只出现延迟(单克隆抗体946±262 vs. 生理盐水1,146±340 pM)。因此,消除GLP-1的作用会损害胃内葡萄糖餐的代谢,这至少部分归因于早期胰岛素释放减少。除了这些餐后效应外,GLP-1拮抗期间空腹血糖和胰高血糖素同时升高表明GLP-1可能对胰高血糖素分泌具有持续的抑制作用。这些发现证明了GLP-1在肠道吸收葡萄糖同化过程中的重要作用。